WallStreetZen

NASDAQ: MRNA
Moderna Inc Stock

$160.50-2.34 (-1.44%)
Updated May 6, 2021
MRNA Price
$160.50
Fair Value Price
N/A
Market Cap
$63.51B
52 Week Low
$46.13
52 Week High
$189.26
P/E
-81.89x
P/B
24.8x
P/S
19.17x
PEG
N/A
Dividend Yield
0%
Revenue
$803.40M
Earnings
$598.17M
Gross Margin
92.6%
Operating Margin
-92.67%
Profit Margin
-93%
Debt to Equity
1.86
Operating Cash Flow
$5B
Beta
0.22
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

MRNA Overview

Zen Score

High
Medium
Low
19
Industry average

Reasons for this score

MRNA is poor value based on its book value relative to its share price (24.8x), compared to the US market average (0.6x)
Valuation
MRNA is poor value based on its book value relative to its share price (24.8x), compared to the US Biotechnology industry average (6.01x)
Valuation
MRNA's Earnings (EBIT) of -$744.51M are insufficient to safely cover interest payments on company debt ($207.30M)
Financials

1 of 7

MRNA News

Valuation

MRNA fair value

Fair Value of MRNA stock based on Discounted Cash Flow (DCF)
Price
$160.50
Fair Value
$169.45
Undervalued by
5.28%

MRNA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-81.89x
Industry
66.59x
Market
27.98x

MRNA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
24.8x
Industry
6.01x
Market
0.6x
MRNA is poor value based on its book value relative to its share price (24.8x), compared to the US market average (0.6x)
Valuation
MRNA is poor value based on its book value relative to its share price (24.8x), compared to the US Biotechnology industry average (6.01x)
Valuation

MRNA's financial health

Profit margin

Revenue
$1.9B
Net Income
$1.2B
Profit Margin
63%
MRNA's Earnings (EBIT) of -$744.51M are insufficient to safely cover interest payments on company debt ($207.30M)
Financials
MRNA's profit margin has increased (+760.7%) in the last year from (-853.7%) to (-93%), but it is still unprofitable
Financials

Assets to liabilities

Assets
$12.7B
Liabilities
$8.9B
Debt to equity
0.06
MRNA's short-term assets ($6.30B) exceed its short-term liabilities ($4.39B)
Financials
MRNA's short-term assets ($6.30B) exceed its long-term liabilities ($386.57M)
Financials
MRNA's debt to equity ratio (1.86) is considered high
Financials

Cash flow

Operating
$3.0B
Investing
-$180.0M
Financing
$26.0M
MRNA's operating cash flow ($2.03B) is sufficient to service the company's debt ($207.30M)
Financials

Moderna Stock FAQ

What is Moderna's quote symbol?

(NASDAQ: MRNA) Moderna trades on the NASDAQ under the ticker symbol MRNA. Moderna stock quotes can also be displayed as NASDAQ: MRNA.

What is the 52 week high and low for Moderna (NASDAQ: MRNA)?

(NASDAQ: MRNA) Moderna's 52-week high was $189.26, and its 52-week low was $46.13. It is currently -15.2% from its 52-week high and 247.93% from its 52-week low.

How much is Moderna stock worth today?

(NASDAQ: MRNA) Moderna currently has 395,710,105 outstanding shares. With Moderna stock trading at $160.50 per share, the total value of Moderna stock (market capitalization) is $63.51B.

Moderna stock was originally listed at a price of $18.60 in Dec 7, 2018. If you had invested in Moderna stock at $18.60, your return over the last 2 years would have been 762.9%, for an annualized return of 193.75%.

How much is Moderna's stock price per share?

(NASDAQ: MRNA) Moderna stock price per share is $160.50 today (as of May 6, 2021).

What is Moderna's Market Cap?

(NASDAQ: MRNA) Moderna's market cap is $63.51B, as of May 9, 2021.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Moderna's market cap is calculated by multiplying MRNA's current stock price of $160.50 by MRNA's total outstanding shares of 395,710,105.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.